CIK 0001990550
AMAM Ambrx Biopharma, Inc.
Insider trading from SEC Form 4. Last filing Mar 7, 2024.
In brief
Ambrx Biopharma, Inc. (AMAM) has 14 SEC Form 4 filings on file from 9 insiders, the latest filed on Mar 7, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at AMAM. The newest: Daniel J. O'Connor (President and CEO) sold $491k of stock on Oct 27, 2023, filed Oct 31, 2023, scored 36 (weak), under a 10b5-1 plan. The largest of the 3 shown: Cormorant Asset Management, LP (10% owner) bought $9.1M on Oct 23, 2023, scored 35 (weak). 2 insiders sold within 14 days of each other around Oct 27, 2023.
7 Form 144 notices of planned sales are on file, the latest filed Dec 26, 2023.
Last 90 days
Signals
Open-market buys and sells at Ambrx Biopharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Daniel J. O'Connor President and CEO sell | $491k 50,012 shares | -13% | - | |
| 21Weak | Sonja Nelson Chief Financial Officer sell | $125k 12,778 shares | -9% | - | |
| 35Weak | Cormorant Asset Management, LP owner buy | $9.1M 1,307,311 shares | +13% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 26, 2023 | HOPU Reunion Co Ltd Affiliated with former director | 1,384,629 2.19% of outstanding | $20M | Dec 26, 2023 | $49M |
| Dec 19, 2023 | HOPU Reunion Co Ltd Affiliated with former director | 1,400,000 2.22% of outstanding | $21M | Dec 19, 2023 | $35M |
| Dec 8, 2023 | HOPU Reunion Co Ltd Affiliated with former director | 1,180,000 1.80% of outstanding | $15M | Dec 8, 2023 | $15M |
| Dec 5, 2023 | HOPU Reunion Co Ltd Affiliated with former director | 1,000,000 1.52% of outstanding | $12M | Dec 5, 2023 | $6.3M |
| Dec 1, 2023 | HOPU Reunion Co Ltd Affiliated with former director | 600,000 0.95% of outstanding | $7.0M | Dec 1, 2023 | none |
| Nov 1, 2023 | O'Connor Daniel J. CEO | 50,012 0.08% of outstanding | $491k | Oct 27, 2023 | none |
| Oct 27, 2023 | Nelson Sonja CFO | 12,778 0.02% of outstanding | $125k | Oct 27, 2023 | none |
Transactions
Every row filed, 37 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | Andrew Aromando Chief Operating Officer | DDisposition to issuer Restricted Stock Unitsderivative | -100,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Janet Loesberg director | DDisposition to issuer Restricted Stock Unitsderivative | -12,142 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Daniel J. O'Connor President and CEO | DDisposition to issuer Common Stock | -48,202 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Paul Maier V director | DDisposition to issuer Restricted Stock Unitsderivative | -12,142 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Stephen C. Glover director | DDisposition to issuer Restricted Stock Unitsderivative | -12,142 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Kate Hermans director | DDisposition to issuer Restricted Stock Unitsderivative | -12,142 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Margaret Dalesandro director | DDisposition to issuer Restricted Stock Unitsderivative | -17,857 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Sonja Nelson Chief Financial Officer | DDisposition to issuer Common Stock | -22,936 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Margaret Dalesandro director | DDisposition to issuer Restricted Stock Unitsderivative | -10,119 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Paul Maier V director | DDisposition to issuer Option to Purchase Common Stockderivative | -30,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Janet Loesberg director | DDisposition to issuer Option to Purchase Common Stockderivative | -30,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Daniel J. O'Connor President and CEO | DDisposition to issuer Restricted Stock Unitsderivative | -294,643 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Stephen C. Glover director | DDisposition to issuer Option to Purchase Common Stockderivative | -30,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Sonja Nelson Chief Financial Officer | DDisposition to issuer Restricted Stock Unitsderivative | -107,143 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Andrew Aromando Chief Operating Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -371,428 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Kate Hermans director | DDisposition to issuer Option to Purchase Common Stockderivative | -30,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Andrew Aromando Chief Operating Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -55,570 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Stephen C. Glover director | DDisposition to issuer Option to Purchase Common Stockderivative | -2,500 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Paul Maier V director | DDisposition to issuer Option to Purchase Common Stockderivative | -15,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Kate Hermans director | DDisposition to issuer Option to Purchase Common Stockderivative | -15,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Daniel J. O'Connor President and CEO | DDisposition to issuer Restricted Stock Unitsderivative | -750,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Janet Loesberg director | DDisposition to issuer Option to Purchase Common Stockderivative | -15,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Sonja Nelson Chief Financial Officer | DDisposition to issuer Restricted Stock Unitsderivative | -50,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Stephen C. Glover director | DDisposition to issuer Option to Purchase Common Stockderivative | -5,714 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Kate Hermans director | DDisposition to issuer Option to Purchase Common Stockderivative | -30,000 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Daniel J. O'Connor President and CEO | DDisposition to issuer Option to Purchase Common Stockderivative | -772,857 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Sonja Nelson Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -367,799 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Daniel J. O'Connor President and CEO | DDisposition to issuer Option to Purchase Common Stockderivative | -173,785 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Sonja Nelson Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -121,427 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Sonja Nelson Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -60,714 | - | - | 0 | Mar 7, 2024 |
| Mar 7, 2024 | Sonja Nelson Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -55,571 | - | - | 0 | Mar 7, 2024 |
| Dec 11, 2023 | Daniel J. O'Connor President and CEO | AGrant or award Common Stock | +750,000 | $0.00 | $0 | 1,363,332 | Dec 11, 2023 |
| Dec 11, 2023 | Sonja Nelson Chief Financial Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 545,776 | Dec 11, 2023 |
| Dec 11, 2023 | Andrew Aromando Chief Operating Officer | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 109,263 | Dec 11, 2023 |
| Oct 27, 2023 | Daniel J. O'Connor President and CEO | SOpen-market sale Common Stock10b5-1 | -50,012 | $9.82 | $491k | 342,845 | Oct 31, 2023 |
| Oct 27, 2023 | Sonja Nelson Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -12,778 | $9.82 | $125k | 130,079 | Oct 31, 2023 |
| Oct 23, 2023 | Cormorant Asset Management, LP owner | POpen-market purchase Common Stockindirect: See Footnotes | +1,307,311 | $6.99 | $9.1M | 11,231,000 | Oct 25, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Andrew AromandoChief Operating Officer
- Cormorant Asset Management, LPowner, other
- Margaret Dalesandrodirector
- Stephen C. Gloverdirector, ceo, officer
- Kate Hermansdirector
- Janet Loesbergdirector
- Paul Maier Vdirector
- Sonja NelsonChief Financial Officer
- Daniel J. O'ConnorPresident and CEO
Questions about AMAM
Answered from the filings on this page, as of the latest one.
Are insiders buying AMAM?
No. In the last 90 days no insider at Ambrx Biopharma, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AMAM on the open market?
Daniel J. O'Connor (President and CEO) sold $491k of AMAM on Oct 27, 2023 and filed the Form 4 on Oct 31, 2023. InsiderTell scored 36 (weak), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Ambrx Biopharma, Inc.?
9 people have filed a Form 4 at Ambrx Biopharma, Inc., among them Andrew Aromando (Chief Operating Officer), Cormorant Asset Management, LP (10% owner), Margaret Dalesandro (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.